Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents

Cancer Research

Volumn 56, Issue 4, 1996, Pages 892-898

  Hawkins, Douglas S ^a   Demers, G William ^a,b   Galloway, Denise A ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53;

ARTICLE; CANCER; CANCER CHEMOTHERAPY; DRUG RESISTANCE; DRUG SENSITIVITY; GENE REPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; APHIDICOLIN; CARBOPLATIN; CELL CYCLE; CELL LINE, TRANSFORMED; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CISPLATIN; EMBRYO; FIBROBLASTS; GENES, P53; GENES, RETINOBLASTOMA; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INFANT, NEWBORN; KINETICS; MALE; MECHLORETHAMINE; MELPHALAN; MICE; ONCOGENE PROTEINS, VIRAL; PACLITAXEL; PAPILLOMAVIRIDAE; REPRESSOR PROTEINS; SKIN; TIME FACTORS;

EID: 0030021996     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Marx, J How cells cycle toward cancer. Science (Washington DC), 263: 319-321, 1994.
2. Cavenee, W. K., and White, R. L. The genetic basis of cancer Sci Am , 272: 72-79, 1995.
3. Hunter, T., and Pines, J. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
4. Hunt, T., and Sherr, C J. Cell multiplication. Editorial overview: Checks and balances. Curr Opin Cell Biol., 6: 833-835, 1994.
5. 1 cyclins. Curr. Opin. Cell Biol., 6: 842-846, 1994.
6. 1 cyclins Cell, 73: 1059-1065, 1993.
7. Peter, M., and Herskowitz, I. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell, 79: 181-184, 1994.
8. Elledge, S. J., and Harper, J. W. CDK inhibitors: on the threshold of checkpoints and development. Curr. Opin. Cell Biol., 6: 847-852, 1994.
9. Nishimoto, T., Uzawa, S , and Schlegel, R. Mitotic checkpoints. Curr. Opin Cell Biol., 4: 174-179, 1992
10. Murray, A. Cell cycle checkpoints. Curr. Opin. Cell Biol., 6: 872-876, 1994.
11. Hartwell, L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell, 71: 543-546, 1992.
12. Kohn, K W., Jackman, J., and O'Connor, P M. Cell cycle control and cancer chemotherapy. J. Cell. Biochem , 54: 440-452, 1994.
13. Hartwell, L. H., and Kastan, M. B. Cell cycle control and cancer. Science (Washington DC), 266: 1821-1828, 1994.
14. Picksley, S. M., and Lane, D. P. p53 and Rb: their cellular roles. Curr. Opin. Cell Biol., 6: 853-858, 1995.
15. Hinds, P. W The retinoblastoma tumor suppressor protein. Curr. Opin. Genet. Dev., 5: 79-83, 1995.
16. Haffner, R. and Oren, M Biochemical properties and biological effects of p53. Curr. Opin. Genet. Dev., 5: 84-90, 1995.
17. 1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
18. Smith, M. L., Chen, I-T., Zhan, Q., Bae, I., Chen, C., Gilmer, T. M., Kastan, M B , O'Connor, P. M., and Fornace, A. J. Interaction of the p53-regulated protein gadd-45 with proliferating cell nuclear antigen. Science (Washington DC), 266: 1376-1380, 1994.
19. Wang, X. W., Forrester, K., Yeh, H., Feitelson, M. A , Gu, J., and Harris, C. C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci USA, 91: 2230-2234, 1994.
20. Wang, X W., Yeh, H., Schaeffer, L., Roy, R., Moncollin, V , Egly, J , Wang, Z., Freidberg, E. C., Evans, M. K., Taffe, B. G., Bohr, V. A., Weeda, G., Hoeijmakers, J. H. J., Forrester, K., and Harris, C. C. p53 modulation of TFIIH-associated nucleotide exision repair activity. Nat. Genet., 10: 188-195, 1995.
21. Lowe, S W , Ruley, H E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74: 957-967, 1993
22. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers Science (Washington DC), 253: 49-53, 1991.
23. Harris, C C , and Hollstein, M Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med., 329: 1318-1327, 1993
24. el Rouby, S. A., Thomas, D C., Rosenberg, C. R., and Potmesil, M. p53 mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression Blood, 82: 3452-3459, 1993.
25. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J P., Chen, S., Nichols, P W , Skinner, D. G., Jones, P. A., and Cote, R. J. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl. J. Med., 331: 1259-1264, 1994.
26. Chellappan, S P , Hiebert, S , Mudruj, M., Horowitz, J. M., and Nevins, J. R. The E2F transcription factor is a cellular target for the RB protein. Cell, 65: 1053-1061, 1991.
27. Horowitz, J M , Park, S-H., Bogenmann, E., Cheng, J-C., Yandell, D. W., Kaye, F. J., Minna, J. D., Dryja, T. P., and Weinberg, R. A. Frequent inactivation of the retinoblastoma antioncogene is restricted to a subset of human tumor cells Proc. Natl. Acad. Sci. USA, 87: 2775-2779, 1990
28. Munger, K., Scheffner, M., Huibregtse, J. M., and Howley, P M. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products Cancer Surv , 12: 197-217, 1992.
29. Scheffner, M , Werness, B A., Huibregtse, J. M., Levine, A. J., and Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63: 129-1136, 1990.
30. zur Hausen, H Human papillomaviruses in the pathogenesis of anogenital cancer Virology. 184: 9-13, 1991.
31. Fan, S., El-Deiry, W. S., Bae, I., Freeman, J , Jondle, D., Bhatia, K., Fornace, A. J., Magrath, I , Kohn, K. W., and O'Connor, P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA-damaging agents. Cancer Res , 54: 5824-5830, 1994.
32. O'Connor, P. M., Jackman, J., Jondle, D., Bhatia, K., Magrath, I., and Kohn, K. W. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53: 4776-4780, 1993.
33. Brachman, D. G., Beckett, M., Graves, D., Haraf, D., Vokes, E , and Weichselbaum, R. R. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res., 53. 3667-3669, 1993.
34. Lowe, S W., Bodis, S., McClatchey, A , Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E , and Jacks, T. p53 status and the efficacy of cancer therapy in vivo Science (Washington DC), 266: 807-810, 1994.
35. Klingelhutz, A. J., Barber, S A , Smith, P. P., Dyer, K., and McDougall, J K. Restoration of telomeres in human papillomavirus-immortalized human anogenital cells. Mol. Cell. Biol., 14: 961-969, 1994.
36. Halbert, C. L., Demers, G. W., and Galloway, D. A. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol., 65: 473-478, 1991
37. Timme, T L , and Thompson, T. C. Rapid allelotype analysis of p53 knockout mice. Biotechniques, 17: 460-463, 1994.
38. Scudiero, D A., Shoemaker, R H , Paull, K D., Monks, A., Tierney, S , Nofzinger, T. H., Currens, M. J., Seniff, D., and Boyd, M. R. Evaluation of a soluble tetrazolium/ formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res., 48: 4827-4833, 1988.
39. Donaldson, K. L., Goolsby, G., Kiener, P. A., and Wahl, A. F. Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth & Differ., 5: 1041-1050, 1994
40. Donaldson, K. L., Goolsby, G. L., and Wahl, A F. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int. J. Cancer, 57. 847-855, 1994.
41. Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tlsty, T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70: 923-935, 1992.
42. Yin, Y , Tainsky, M A., Bischoff, F. Z., Strong, L. C., and Wahl, G. M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70: 937-948, 1992.
43. Cross, S. M., Sanchez, C. A., Morgan, C. A., Schimke, M. K., Ramel, S., Idzerda, R. L. Raskind, W. H , and Reid, B. J A p53-dependent mouse spindle checkpoint Science (Washington DC), 267: 1353-1356, 1995.
44. Fisher, D E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
45. Fan, S., Smith, M. L., Rivet, D. J., Duba, D., Zhan, Q , Kohn, K. W., Fornace, A. J , and O'Connor, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.
46. Dijt, F. J., Fichtinger-Schepman, A M., Berends, F., and Reedijk, J. Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res., 48: 6058-6062, 1988.
47. Clarke, A. R., Maandag, E. R., van Roon, M., van der Lugt, N. M., van der Valk, M., Hooper, M. L., Berns, A., and Riele, H. T. Requirement for a functional Rb-1 gene in murine development. Nature (Lond.), 359. 328-330, 1992.
48. Komblau, S. M., Xu, H. J., Zhang, W., Hu, S. X., Beran, M., Smith, T. L., Hester, J , Estey, E., Benedict, W. F. and Deisseroth, A. B. Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. Blood, 84: 256-261, 1994.
49. Logothetis, C. J , Xu, H. J., Ro, J. Y., Hu, S. X., Sahin, A., Ordonez, N , and Benedict W. F. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl. Cancer Inst., 84: 1256-1261, 1992.
50. Demers, G. W., Foster, S. A. Halbert, C. L., and Galloway, D. A. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc. Natl. Acad. Sci. USA, 91: 4382-4386, 1994.